Clinical trial
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
NCT00878449 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- July 31, 2011
- Enrollment
- 12 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors